Aberrant activation of NF-κB, a downstream transcription factor of the TLR pathway, is a hallmark of glioma [195]. Inhibition of these signaling pathways results in significant programmed death of glioma cells, and these inhibitors can be used as therapeutic adjuvants to the TMZ standard chemotherapy for glioma [196]. The gene discussed is NFKB1; the disease is glioma.